Information Provided By:
Fly News Breaks for September 15, 2017
SRPT
Sep 15, 2017 | 07:56 EDT
As noted earlier, RBC Capital started coverage of Sarepta with a $64 price target and an Outperform rating. Analyst Matt Eckler identified the company as one of his top small/mid-cap biotech picks. The analyst says that the commercial opportunity of the company's Exondys 51 is greater than the market believes, while the company's pipeline is "underappreciated" and it has other potential catalysts.
News For SRPT From the Last 2 Days
There are no results for your query SRPT